Edges in Network
| Network | GSE18864_egf1520 - GSE18864 - SiGN-BN HC+Bootstrap |
| Network Description | Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients |
| Node | SLC16A6 |
| Upstream (Parents) |
|---|
| (<<) ABCF1 → SLC16A6 |
| (<<) ARHGEF2 → SLC16A6 |
| (<<) CASC4 → SLC16A6 |
| (<<) CCNE1 → SLC16A6 |
| (<<) CPD → SLC16A6 |
| (<<) CSNK1A1 → SLC16A6 |
| (<<) CSTB → SLC16A6 |
| (<<) DAZAP2 → SLC16A6 |
| (<<) ENO1 → SLC16A6 |
| (<<) ITCH → SLC16A6 |
| (<<) MAP2K3 → SLC16A6 |
| (<<) MLPH → SLC16A6 |
| (<<) MREG → SLC16A6 |
| (<<) ODC1 → SLC16A6 |
| (<<) PHGDH → SLC16A6 |
| (<<) PLEKHF1 → SLC16A6 |
| (<<) RHOB → SLC16A6 |
| (<<) TMEM45B → SLC16A6 |
| Downstream (Children) |
|---|
| SLC16A6 → ARL4C (>>) |
| SLC16A6 → BRAF (>>) |
| SLC16A6 → CCND1 (>>) |
| SLC16A6 → CXCR7 (>>) |
| SLC16A6 → DNAJA4 (>>) |
| SLC16A6 → DOK7 (>>) |
| SLC16A6 → DUSP4 (>>) |
| SLC16A6 → ELF5 (>>) |
| SLC16A6 → EPHB3 (>>) |
| SLC16A6 → EZR (>>) |
| SLC16A6 → FAM110C (>>) |
| SLC16A6 → FOS (>>) |
| SLC16A6 → GAD1 (>>) |
| SLC16A6 → GNB2 (>>) |
| SLC16A6 → GNG12 (>>) |
| SLC16A6 → GSTM3 (>>) |
| SLC16A6 → HOPX (>>) |
| SLC16A6 → HSP90AB1 (>>) |
| SLC16A6 → HSPA2 (>>) |
| SLC16A6 → KHDRBS3 (>>) |
| SLC16A6 → NAGS (>>) |
| SLC16A6 → NCOA3 (>>) |
| SLC16A6 → NFIA (>>) |
| SLC16A6 → NFIB (>>) |
| SLC16A6 → NFKBIZ (>>) |
| SLC16A6 → PCDH7 (>>) |
| SLC16A6 → PKIB (>>) |
| SLC16A6 → PLA2G12A (>>) |
| SLC16A6 → RNASE4 (>>) |
| SLC16A6 → STAT2 (>>) |
| SLC16A6 → STC2 (>>) |
| SLC16A6 → TCEAL1 (>>) |
| SLC16A6 → TCOF1 (>>) |
| SLC16A6 → TFF1 (>>) |
| SLC16A6 → TWIST2 (>>) |
| SLC16A6 → UBE2I (>>) |
| SLC16A6 → VAV3 (>>) |
